Experts Caution on Prescribing Obesity Medications Amid Rising Popularity of GLP-1 Drugs

The use of glucagon-like peptide-1 (GLP-1) receptor agonists such as Ozempic, Wegovy, and Mounjaro has surged in recent years, transitioning from primarily managing Type 2 diabetes to becoming a popular tool for weight loss among many Americans. Current data indicates that approximately one in eight individuals in the U.S. have received a prescription for these medications, reflecting their growing influence.

However, leading obesity researchers from Temple University, David B. Sarwer and Leah M. Schumacher, express concerns over how some plastic surgeons are promoting and prescribing these drugs. They emphasize the importance of understanding obesity as a chronic disease rather than merely a cosmetic issue, urging physicians to adopt comprehensive, evidence-based approaches to treatment.

In their recent publication, "Considerations for the Use of Glucagon-like Peptide-1 Medications for Obesity in a Plastic Surgery Setting," they recommend that plastic surgeons pursue additional training in obesity management and provide substantial support to patients undergoing medication therapy. Sarwer notes that GLP-1 medications are initially designed for individuals with significant health problems related to weight, not for those seeking minor cosmetic weight loss, such as a 10-20 pound reduction.

The researchers highlight that obesity is associated with numerous health complications, including hypertension, diabetes, and cardiovascular disease, which require careful assessment and management. They caution against the oversimplified marketing of GLP-1s as quick cosmetic fixes, as this can perpetuate bias, stigma, and misinformation about obesity.

Since the American Medical Association classified obesity as a disease in 2013, the understanding of its complexity has evolved. It is now recognized as a condition influenced by genetic, physiological, and systemic factors, necessitating a multi-faceted treatment approach. Despite this, some plastic surgeons continue to treat obesity as a cosmetic concern, offering GLP-1s without comprehensive support or consideration of other effective options like lifestyle modifications or bariatric surgery.

Sarwer and Schumacher advocate for a more responsible and informed use of these medications. They stress that successful obesity treatment involves integrated support, including nutritional counseling, behavioral therapy, and physical activity, along with medication.

Finally, the authors call for improved training for healthcare providers in obesity management, emphasizing that addressing obesity effectively requires more than just prescribing medication. They maintain that a broad understanding and responsible application of various treatment modalities are essential to improve patient outcomes and reduce the stigma surrounding obesity.

Source: https://medicalxpress.com/news/2025-09-obesity-medications-popularity-experts-issue.html